These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 30684230

  • 1. 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers.
    Souteiro P, Gouveia P, Ferreira G, Belo S, Costa C, Carvalho D, Duarte H, Sampaio IL.
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [Abstract] [Full Text] [Related]

  • 2. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND 18F-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF 18F-FDG PET/CT.
    Yang JH, Camacho CP, Lindsey SC, Valente FOF, Andreoni DM, Yamaga LY, Wagner J, Biscolla RPM, Maciel RMB.
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.
    Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, Martínez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, Navarro-González E.
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [Abstract] [Full Text] [Related]

  • 4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA, Kunert-Radek J, Pomorski L.
    Endokrynol Pol; 2006 Nov; 57(4):452-5. PubMed ID: 17006852
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
    Hell J Nucl Med; 2015 Nov; 18(1):19-24. PubMed ID: 25679074
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer.
    Şahin OE, Uslu-Beşli L, Asa S, Sağer S, Sönmezoğlu K.
    Hell J Nucl Med; 2020 Nov; 23(3):321-329. PubMed ID: 33367304
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
    Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, Ambrosini V, Cremonini N, Santimaria M, Versari A, Fanti S, Giordano A, Rufini V.
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vázquez-Albertino RJ, Navarro-González E, Ruiz-Franco-Baux JV, Cuenca-Cuenca JI.
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
    [Abstract] [Full Text] [Related]

  • 12. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
    Şahin E, Elboğa U.
    J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
    [Abstract] [Full Text] [Related]

  • 13. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
    Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD.
    Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
    [Abstract] [Full Text] [Related]

  • 14. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, Bal C.
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [Abstract] [Full Text] [Related]

  • 15. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW, Chen YK.
    World J Surg Oncol; 2017 Dec 29; 15(1):230. PubMed ID: 29284496
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.
    Kundu P, Lata S, Sharma P, Singh H, Malhotra A, Bal C.
    Eur J Nucl Med Mol Imaging; 2014 Jul 29; 41(7):1354-62. PubMed ID: 24562651
    [Abstract] [Full Text] [Related]

  • 17. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F.
    J Clin Endocrinol Metab; 2007 Dec 29; 92(12):4590-7. PubMed ID: 17878252
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, Adalet I.
    Nucl Med Commun; 2015 Mar 29; 36(3):242-50. PubMed ID: 25369749
    [Abstract] [Full Text] [Related]

  • 19. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W.
    Cancer; 1997 Dec 15; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [Abstract] [Full Text] [Related]

  • 20. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
    Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP.
    J Nucl Med; 2008 Apr 15; 49(4):524-31. PubMed ID: 18375923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.